All In Biotech

Free tool

FAERS Monitor: Steqeyma

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761338 or its brand name (Steqeyma, Ustekinumab-Stba). Reports on generic versions are filed under their own applications.

Reports

371

Serious

293

79% of reports

Hospitalization

78

Death reported

22

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • intentional product use issue49
  • suspected off label use45
  • crohn^s disease41
  • off label use35
  • drug dose omission by device34
  • intentional dose omission28
  • accidental exposure to product24
  • exposure via skin contact24
  • condition aggravated21
  • needle issue21
  • death20
  • device malfunction19
  • product dose omission issue18
  • fatigue15
  • inappropriate schedule of product administration15

Reports by year received

View as table
YearReports
20241
2025144
2026226

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,788 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
suspected off label useSignal45570.4433.124,768
intentional dose omissionSignal2855.739.01,451
exposure via skin contactSignal2452.635.71,163
needle issueSignal2140.927.0779
intentional product use issueSignal4931.724.41,433
drug dose omission by deviceSignal3424.617.9750
device malfunctionSignal1915.39.9241
accidental exposure to productSignal2413.29.0260
inappropriate schedule of product administrationSignal154.72.941
condition aggravatedSignal213.92.643
product dose omission issueSignal183.52.230
off label useSignal352.31.725
death201.30.91
fatigue151.10.70
crohn^s disease410.00.02,270,300

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.